Drug-Drug Interactions and HIV/Hepatitis C Virus Coinfection
Thursday, August 31, 2017
1:00 PM (ET), 12:00 PM (CT), 11:00 AM (MT), 10:00 AM (PT)
Assessment of Needs
The IAS–USA offers this state-of-the-art activity on the evolving challenges of managing HCV disease as part of a nationwide continuing medical education (CME) effort for physicians. The potential for drug-drug interactions is an important consideration in the treatment of hepatitis C virus (HCV) infection in HIV/HCV-coinfected individuals. Regimens for HCV infection are discussed in this webinar in the context of a coinfected individual, to determine which HCV treatments may be initiated without requiring a change in antiretroviral regimen or an increase in monitoring for potential drug-drug interactions. The effects of potential interactions between HCV drugs and other therapeutic classes of drugs are also addressed.
At the conclusion of this webinar, learners will be able to:
- Identify antiretroviral drugs with the potential for drug interactions with therapies for HCV infection
- Develop a plan for managing drug-drug interactions when treating HCV infection in HIV/HCV-coinfected individuals
Who Should Attend
This webinar is designed for physicians who have a good understanding of the basics of HCV transmission, testing, and management, and have managed HCV infection in at least 5 patients.
This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, August 30, 2017, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.